Suramin suppresses growth, alkaline-phosphatase and telomerase activity of human osteosarcoma cells in vitro

International Journal of Biochemistry and Cell Biology

Volumn 35, Issue 7, 2003, Pages 1066-1070

  Trieb, K ^a   Blahovec, H ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Alkaline phosphatase; Growth; Osteosarcoma; Suramin; Telomerase; Treatment

Indexed keywords

ALKALINE PHOSPHATASE; CALCITRIOL; SURAMIN; TELOMERASE; THYMIDINE;

ADOLESCENT; ARTICLE; CASE REPORT; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME RELEASE; ENZYME REPRESSION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; OSTEOSARCOMA CELL; SCHOOL CHILD;

ALKALINE PHOSPHATASE; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CELL DIVISION; HUMANS; OSTEOSARCOMA; SURAMIN; TELOMERASE; TUMOR CELLS, CULTURED;

EID: 0037411184     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1357-2725(02)00308-4     Document Type: Article

References (19)

1. Benini S., Baldini N., Manara M., Chano T., Serra M., Rizzi S., Lollini P., Picci P., Scotlandi K. Redundancy of autocrine loops in human osteosarcoma cells. International Journal of Cancer. 80:1999;581-588.
2. Bieling B., Rehan N., Winkler P., Helmke K., Maas R., Fuchs U., Bielak S., Heis U., Jürgens H., Treuner J., Romanowski R., Exner U., Kotz R., Winkler K. Tumor size and prognosis in aggressively treated osteosarcoma. Journal of Clinical Oncology. 14:1996;848-858.
3. Farley J. Phosphate regulates the stability of skeletal phosphatase in human osteosarcoma (SaOS-2) cells without equivalent effects on the level of skeletal alkaline-phosphatase immunoreactive protein. Calciferous Tissue. 57:1995;371-378.
4. Geidel S., Garn M., Gravighoff L. Cardiomyopathy after osteosarcoma treatment: a contribution to the cardiotoxicity of adriamycin. Klinische Pedriatic. 203:1991;257-261.
5. Grossmann S.A., Phuphanich S., Lesser G., Rozental J., Grochow L.B., Fischer J., Piantadosi S. Toxicity, efficacy, and pharmacology of suramin in adults with recurrent high-grade gliomas. Journal of Clinical Oncology. 19:2001;3260-3266.
6. Hawking F. Suramin: with special reference to onchocerciasis. Advance Pharmaceutical Chemotherapy. 15:1978;289-322.
7. Kloen P., Jennings C., Gebhardt M., Springfield D., Mankin H. Suramin inhibits growth and transforming growth factor-β1 (TGF-β1) binding in osteosarcoma cell lines. European Journal of Cancer. 30:1994;678-682.
8. Mills G., Zhang N., May C., Hill A., Chung A. Suramin prevents binding of interleukin 2 to its cell surface receptor: a possible mechanism for immunosuppression. Cancer Research. 50:1990;3036-3042.
9. Rosen G., Marcove R., Caparros B., Nierenberg A., Kosloff C.C., Huvos A. Primary osteogenic sarcoma: the rationale of preoperative chemotherapy and delayed surgery. Cancer. 43:1979;2163-2177.
10. Ryan C., Vokes E., Vogelzang N., Janisch L., Kobayashi K., Ratain M. A phase I study of suramin with once- or twice-monthly dosing in patients with advanced cancer. Cancer Chemotherapy and Pharmacology. 50:2002;1-5.
11. Salzer-Kuntschik M., Brand G., Delling G. Bestimmung des morphologischen Regressionsgrades nach Chemotherapie bei malignen Knochentumoren. Pathologe. 4:1983;135-141.
12. Scotlandi K., Serra M., Nicoletti G. Multidrug resistance and malignancy in human osteosarcoma. Cancer Research. 56:1996;2434-2439.
13. Small E., Halbali S., Ratain M., Rosner G., Stadler W., Palchak D., Marshall E., Rago R., Hars V., Wilding G., Petrylak D., Vogelzang N. Randomized study of three different doses of suramin administered with a fix dosind schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480. Journal of Clinical Oncology. 20:2002;3369-3375.
14. Trieb K., Dorfinger K., Neuhold N., Selzer E., Wilfing A., Czernin S., Hermann M., Niederle B., Gessl A., Vierhapper H., Grubeck-Loebenstein B. Suramin affects differentiated and undifferentiated thyroid epithelial cells in vitro. Journal of Endocrinology. 134:1992;505-511.
15. Trieb K., Lang S., Kotz R. Heat shock protein 72 in human osteosarcoma: T-lymphocyte reactivity and cytotoxicity. Pediatric Hematology and Oncology. 17:2000a;1-10.
16. Trieb K., Thurnherr D., Bakroeva M., Kotz R., Kornfehl J. Reversible downregulation of telomerase activity by hyperthermia in osteosarcoma cells. International Journal of Hyperthermia. 16:2000b;445-448.
17. Urasawa K., Kaneta S., Nakano N., Saito T., Sakai H., Takagi C., Takagi Y., Sugiki H., Kitabatake A. Vascular smooth muscle cell proliferation is effectively suppressed by the non-specific growth factor inhibitor suramin. Japanese Heart Journal. 42:2001;221-223.
18. Vierhapper H., Nowotny P., Mostbeck G., Waldhäusl W. Effect of suramin in a patient with adrenocortical carcinoma. Lancet. 27:1989;1207-1208.
19. Winkler K., Beron G., Kotz R. Neoadjuvant chemotherapy for osteogenic sarcoma: results of a cooperative German/Austrian study. Journal of Clinical Oncology. 2:1984;617-624.